Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + L-glutamate + H2O
LL-2,6-diaminoheptanedioate + 2-oxoglutarate
Substrates: -
Products: -
?
L-2-amino-6-oxopimelate + L-glutamate + H2O
LL-2,6-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
LL-diaminopimelate + 2-oxoglutarate
LL-2,6-diaminoheptanedioate + 2-oxoglutarate
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + L-glutamate + H2O
LL-2,6-diaminopimelate + 2-oxoglutarate
2,3,4,5-tetrahydrodipicolinate + L-glutamate + H2O
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
LL-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
meso-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
additional information
?
-
L-2-amino-6-oxopimelate + L-glutamate + H2O
LL-2,6-diaminopimelate + 2-oxoglutarate
-
Substrates: -
Products: -
?
L-2-amino-6-oxopimelate + L-glutamate + H2O
LL-2,6-diaminopimelate + 2-oxoglutarate
Substrates: -
Products: -
r
L-2-amino-6-oxopimelate + L-glutamate + H2O
LL-2,6-diaminopimelate + 2-oxoglutarate
-
Substrates: -
Products: -
r
L-glutamate + tetrahydrodipicolinate + H2O
LL-diaminopimelate + 2-oxoglutarate
-
Substrates: slightly active (1%-2%) with meso-diaminopimelate, lysine and L-ornithine
Products: -
r
L-glutamate + tetrahydrodipicolinate + H2O
LL-diaminopimelate + 2-oxoglutarate
-
Substrates: -
Products: -
r
L-glutamate + tetrahydrodipicolinate + H2O
LL-diaminopimelate + 2-oxoglutarate
-
Substrates: -
Products: -
r
L-glutamate + tetrahydrodipicolinate + H2O
LL-diaminopimelate + 2-oxoglutarate
Substrates: no activity observed with pyruvate, prephenate, oxaloacetate and oxovalerate
Products: -
r
L-glutamate + tetrahydrodipicolinate + H2O
LL-diaminopimelate + 2-oxoglutarate
-
Substrates: -
Products: -
r
L-glutamate + tetrahydrodipicolinate + H2O
LL-diaminopimelate + 2-oxoglutarate
Substrates: no activity observed with pyruvate, prephenate, oxaloacetate and oxovalerate
Products: -
r
L-glutamate + tetrahydrodipicolinate + H2O
LL-diaminopimelate + 2-oxoglutarate
-
Substrates: -
Products: -
r
LL-2,6-diaminoheptanedioate + 2-oxoglutarate
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + L-glutamate + H2O
Substrates: -
Products: -
r
LL-2,6-diaminoheptanedioate + 2-oxoglutarate
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + L-glutamate + H2O
Substrates: -
Products: -
r
LL-2,6-diaminoheptanedioate + 2-oxoglutarate
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminoheptanedioate + 2-oxoglutarate
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminoheptanedioate + 2-oxoglutarate
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + L-glutamate + H2O
WP_009961032
Substrates: -
Products: -
?
LL-2,6-diaminoheptanedioate + 2-oxoglutarate
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + L-glutamate + H2O
Substrates: -
Products: -
r
LL-2,6-diaminoheptanedioate + 2-oxoglutarate
(S)-2,3,4,5-tetrahydropyridine-2,6-dicarboxylate + L-glutamate + H2O
-
Substrates: -
Products: -
r
LL-2,6-diaminopimelate + 2-oxoglutarate
2,3,4,5-tetrahydrodipicolinate + L-glutamate + H2O
-
Substrates: slightly active (1%-8%) with meso-diaminopimelate, L-lysine, L-ornithine, pyruvate, oxaloacetate and oxovalerate
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
2,3,4,5-tetrahydrodipicolinate + L-glutamate + H2O
-
Substrates: slightly active (1%-8%) with meso-diaminopimelate, L-lysine, L-ornithine, pyruvate, oxaloacetate and oxovalerate
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
r
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-2,6-diaminopimelate + 2-oxoglutarate
L-2-amino-6-oxopimelate + L-glutamate + H2O
Substrates: -
Products: -
?
LL-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
-
Substrates: -
Products: -
r
LL-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
Substrates: -
Products: -
?
LL-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
-
Substrates: also active (17%-21%) with lysine, L-ornithine and cystathionine
Products: -
r
LL-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
-
Substrates: -
Products: -
r
LL-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
Substrates: no activity observed with meso-diaminopimelate, L-lysine and L-ornithine
Products: -
r
LL-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
-
Substrates: -
Products: -
r
LL-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
Substrates: no activity observed with meso-diaminopimelate, L-lysine and L-ornithine
Products: -
r
LL-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
-
Substrates: -
Products: -
r
meso-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
-
Substrates: -
Products: -
r
meso-diaminopimelate + 2-oxoglutarate
L-glutamate + tetrahydrodipicolinate + H2O
Substrates: -
Products: -
?
additional information
?
-
-
Substrates: no substrate: m-diaminopimelate, lysine, ornithine, no amino acceptor: oxaloacetate, pyruvate
Products: -
?
additional information
?
-
Substrates: no substrate: m-diaminopimelate, lysine, ornithine, no amino acceptor: oxaloacetate, pyruvate
Products: -
?
additional information
?
-
Substrates: enzyme in the biosynthesis of L-lysine
Products: -
?
additional information
?
-
-
Substrates: enzyme in the biosynthesis of L-lysine
Products: -
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2-[(E)-[1-(4-chlorophenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
14% inhibition at 0.01 mM
(2-[(E)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
(2-[(E)-[1-methyl-3-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
17% inhibition at 0.01 mM
(2E)-2-cyano-3-[5-(dimethylamino)furan-2-yl]-N-(3,4-dimethylphenyl)prop-2-enamide
-
14% inhibition at 0.01 mM
(2Z)-N'-nitro-2-[[5-(3-nitrophenyl)furan-2-yl]methylidene]hydrazinecarboximidamide
-
13% inhibition at 0.01 mM
(3E)-1-[(4-methoxyphenyl)sulfonyl]-3-[4-oxo-3-(prop-2-en-1-yl)-2-thioxo-1,3-thiazolidin-5-ylidene]-1,3-dihydro-2H-indol-2-one
-
18% inhibition at 0.01 mM
(3E)-1-[(4-methylphenyl)sulfonyl]-3-(4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene)-1,3-dihydro-2H-indol-2-one
-
25% inhibition at 0.01 mM
(3E)-3-[2-(2,4-dimethyl-1,3-thiazol-5-yl)-2-oxoethylidene]-3,4-dihydroquinoxalin-2(1H)-one
-
18% inhibition at 0.01 mM
(3E)-3-[2-oxo-2-(thiophen-2-yl)ethylidene]-3,4-dihydroquinoxalin-2(1H)-one
-
15% inhibition at 0.01 mM
(3Z)-3-(2,4-dimethoxybenzylidene)-5-phenylfuran-2(3H)-one
-
14% inhibition at 0.01 mM
(5E)-5-(1H-indol-2-ylmethylidene)-1-(4-methylphenyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
16% inhibition at 0.01 mM
(5E)-5-[(1-benzyl-1H-indol-2-yl)methylidene]-1-(2-methoxyphenyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
20% inhibition at 0.01 mM
(5E)-5-[(1-methyl-1H-indol-2-yl)methylidene]-1-(prop-2-en-1-yl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
35% inhibition at 0.01 mM
(5E)-5-[(1-methyl-1H-indol-2-yl)methylidene]-1-prop-2-en-1-yl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
45% inhibition at 0.01 mM
(5E)-5-[[1-(4-nitrobenzyl)-1H-indol-2-yl]methylidene]-1-(prop-2-en-1-yl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
33% inhibition at 0.01 mM
(5Z)-1-(3-bromophenyl)-5-(furan-2-ylmethylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
17% inhibition at 0.01 mM
(5Z)-3-(1,1-dioxidotetrahydrothiophen-3-yl)-5-[[1-phenyl-3-(thiophen-2-yl)-1H-pyrazol-4-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-(3-iodo-4-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
-
29% inhibition at 0.01 mM
(5Z)-5-[(3-methylthiophen-2-yl)methylidene]-3-(1-phenylethyl)-2-thioxo-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-[(3-methylthiophen-2-yl)methylidene]-3-(tetrahydrofuran-2-ylmethyl)-2-thioxo-1,3-thiazolidin-4-one
-
14% inhibition at 0.01 mM
(5Z)-5-[(6-bromo-1,3-benzodioxol-5-yl)methylidene]-2-(4-methylphenyl)-1,3-thiazol-4(5H)-one
-
13% inhibition at 0.01 mM
(5Z)-5-[5-(2-chlorobenzyl)-2-hydroxybenzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
(5Z)-5-[[5-(2-bromo-4-nitrophenyl)furan-2-yl]methylidene]-2-imino-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-1-(4-methoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
-
20% inhibition at 0.01 mM
(Z)-3-amino-5-(4-methoxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-3-ethyl-5-(2-hydroxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-3-ethyl-5-(4-methoxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-3-ethyl-5-(naphthalen-1-ylmethylene)-2-thioxothiazolidin-4-one
-
-
(Z)-3-ethyl-5-(quinolin-5-ylmethylene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-(2-hydroxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-(4-(dimethylamino)benzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-(4-chlorobenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-(4-chlorobenzylidene)-3-ethyl-2-thioxothiazolidin-4-one
-
-
(Z)-5-(4-methoxybenzylidene)-2-thioxothiazolidin-4-one
-
-
(Z)-5-benzylidene-3-ethyl-2-thioxothiazolidin-4-one
-
-
(Z)-N -(5-((5-(4-nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetamide
-
-
(Z)-N-(5-(4-methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetamide
-
-
1,3-bis((7-chloro-4-quinolinyl)amino)-2-propanol
-
NSC_5485, potential drug candidate that can inhibit the enzymatic activity of enzyme CtDAP-AT
1,3-dimethyl-5-[[1-(3-nitrophenyl)-1H-pyrrol-2-yl]methylidene]pyrimidine-2,4,6(1H,3H,5H)-trione
-
13% inhibition at 0.01 mM
1-(4-fluorophenyl)-2-[[4-phenyl-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazol-3-yl]sulfanyl]ethanone
-
14% inhibition at 0.01 mM
2-(2-[(E)-[1-(4-fluorophenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)-N-phenylacetamide
-
18% inhibition at 0.01 mM
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
2-[(2E)-2-(2-oxo-5-phenylfuran-3(2H)-ylidene)hydrazinyl]benzoic acid
-
16% inhibition at 0.01 mM
2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide
3-cyclopropyl-N'-[(1E)-1-(4-methylphenyl)ethylidene]-1H-pyrazole-5-carbohydrazide
-
14% inhibition at 0.01 mM
3-[2-[(4-acetylphenyl)amino]-1,3-thiazol-4-yl]-2H-chromen-2-one
-
16% inhibition at 0.01 mM
4-chloro-N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
4-fluoro-N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
4-[(E)-[2-(2-chlorophenyl)-5-oxo-1,3-oxazol-4(5H)-ylidene]methyl]-2-hydroxyphenyl 2-chlorobenzoate
-
30% inhibition at 0.01 mM
5-(4-methylphenyl)-4-[[(E)-(2,4,5-trimethoxyphenyl)methylidene]amino]-4H-1,2,4-triazole-3-thiol
-
18% inhibition at 0.01 mM
5-([1-[2-(3,4-dimethylphenoxy)ethyl]-1H-indol-2-yl]methylidene)pyrimidine-2,4,6(1H,3H,5H)-trione
-
28% inhibition at 0.01 mM
5-[(5-hydroxy-1-phenyl-1H-pyrazol-4-yl)methylidene]-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione
-
20% inhibition at 0.01 mM
5-[3-[(2-chlorobenzyl)oxy]-4-methoxybenzylidene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
-
48% inhibition at 0.01 mM
8-methoxy-3-[(2-methylprop-2-en-1-yl)oxy]-6H-benzo[c]chromen-6-one
-
25% inhibition at 0.01 mM
Barbiturate
binding structure model
ethyl (5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-2-[(4-methoxyphenyl)amino]-4-oxo-4,5-dihydrothiophene-3-carboxylate
-
22% inhibition at 0.01 mM
ethyl (5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-2-[(4-nitrophenyl)amino]-4-oxo-4,5-dihydrothiophene-3-carboxylate
-
19% inhibition at 0.01 mM
ethyl 4-(5-[(Z)-[2,4,6-trioxo-1-(prop-2-en-1-yl)tetrahydropyrimidin-5(2H)-ylidene]methyl]furan-2-yl)benzoate
-
16% inhibition at 0.01 mM
hydrazide
binding structure model
N'-[(E)-(2,4-dihydroxyphenyl)methylidene]-5-nitro-3-phenyl-1H-indole-2-carbohydrazide
-
15% inhibition at 0.01 mM
N'-[(Z)-(4-fluorophenyl)methylidene]-3-(naphthalen-2-yl)-1H-pyrazole-5-carbohydrazide
-
14% inhibition at 0.01 mM
N-[(2E,5Z)-5-[[5-(4-nitrophenyl)furan-2-yl]methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]acetamide
-
52% inhibition at 0.01 mM
N-[(5E)-5-[(5-bromofuran-2-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetamide
-
13% inhibition at 0.01 mM
N-[(5Z)-5-[(5-bromofuran-2-yl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetamide
-
-
N-[2-(hydrazinylcarbonyl)-4,5-dimethoxyphenyl]benzenesulfonamide
-
-
N-[2-(hydrazinylcarbonyl)-5-(trifluoromethyl)phenyl]benzenesulfonamide
-
-
N-[2-(hydrazinylcarbonyl)-5-methoxyphenyl]benzenesulfonamide
-
-
N-[2-(hydrazinylcarbonyl)-5-methylphenyl]benzenesulfonamide
-
-
N-[2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
N-[3-(hydrazinylcarbonyl)naphthalen-2-yl]benzenesulfonamide
N-[3-[(2,5-dimethoxyphenyl)amino]quinoxalin-2-yl]-3-nitrobenzenesulfonamide
-
13% inhibition at 0.01 mM
N-[4,5-difluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
N-[5-chloro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]-4-methoxybenzenesulfonamide
-
-
N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]-4-methylbenzenesulfonamide
-
-
N-[5-fluoro-2-(hydrazinylcarbonyl)phenyl]benzenesulfonamide
-
-
N-[[2-(2-chlorophenyl)-1,3-benzoxazol-5-yl]carbamothioyl]-3-methyl-1-benzofuran-2-carboxamide
-
19% inhibition at 0.01 mM
rhodanine
binding structure model
thiobarbiturate
binding structure model
(2-[(E)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
(2-[(E)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
-
(2-[(E)-[1-(4-methylphenyl)-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene]methyl]-1H-indol-1-yl)acetic acid
WP_009961032
-
(5Z)-5-[5-(2-chlorobenzyl)-2-hydroxybenzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
13% inhibition at 0.01 mM
(5Z)-5-[5-(2-chlorobenzyl)-2-hydroxybenzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
(5Z)-5-[5-(2-chlorobenzyl)-2-hydroxybenzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
(5Z)-5-[5-(2-chlorobenzyl)-2-hydroxybenzylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
WP_009961032
-
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
-
15% inhibition at 0.01 mM
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
-
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
-
2-thioxo-5-[(1,2,5-trimethyl-1H-pyrrol-3-yl)methylidene]dihydropyrimidine-4,6(1H,5H)-dione
WP_009961032
-
2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide
-
2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide
-
N-[3-(hydrazinylcarbonyl)naphthalen-2-yl]benzenesulfonamide
-
33% inhibition at 0.01 mM
N-[3-(hydrazinylcarbonyl)naphthalen-2-yl]benzenesulfonamide
-
-
N-[3-(hydrazinylcarbonyl)naphthalen-2-yl]benzenesulfonamide
-
N-[3-(hydrazinylcarbonyl)naphthalen-2-yl]benzenesulfonamide
-
N-[3-(hydrazinylcarbonyl)naphthalen-2-yl]benzenesulfonamide
WP_009961032
-
additional information
-
not inhibitory: m-diaminopimelate, lysine, ornithine
-
additional information
not inhibitory: m-diaminopimelate, lysine, ornithine
-
additional information
-
not inhibited by (Z)-5-benzylidene-2-thioxothiazolidin-4-one, (Z)-5-(naphthalen-1-ylmethylene)-2-thioxothiazolidin-4-one, (Z)-3-amino-5-benzylidene-2-thioxothiazolidin-4-one, (Z)-3-amino-5-(4-chlorobenzylidene)-2-thioxothiazolidin-4-one, (Z)-N-(5-benzylidene-4-oxo-2-thioxothiazolidin-3-yl)-acetamide, (Z)-N-(5-(4-chlorobenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetamide, and (Z)-5-(2-nitrobenzylidene)-2-thioxothiazolidin-4-one
-
additional information
-
high-throughput virtual screening for potential enzyme inhibitors using the optimized and corrected PLP-bound L,Ldiaminopimelate aminotransferase structure based on the crystal structure, PDB ID 3ASB. Comparative molecular dynamics simulation studies of enzyme CtDAP-AT in apoform and in complex with potential inhibitors, intermolecular interaction profiling of the compounds in complex with CtDAP-AT
-
additional information
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. The enzymes respond differently to the inhibitors
-
additional information
-
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. The enzymes respond differently to the inhibitors
-
additional information
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. the enzymes respond differntly to the inhibors
-
additional information
-
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. the enzymes respond differntly to the inhibors
-
additional information
WP_009961032
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. The enzymes respond differently to the inhibitors. 2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide is not inhibitory with Verrucomicrobium spinosum DapL
-
additional information
-
comprehensive inhibition study comparing the kinetic activity of DapL orthologs using small molecule inhibitors and recombinant enzymes from Leptospira interrogans, Verrucomicrobium spinosum and Chlamydomonas reinhardtii. Enzyme active sites are conserved, although the second shell of residues close to the active site are not. The enzymes respond differently to the inhibitors. 2-[2-[(E)-(4,6-dioxo-1-phenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]-1H-indol-1-yl]-N-phenylacetamide is not inhibitory with Verrucomicrobium spinosum DapL
-
additional information
rhodanine, barbiturate, hydrazide, and thiobarbiturate associations with VsDapL are supported by molecular dynamics simulations, docking study, overview
-
additional information
-
rhodanine, barbiturate, hydrazide, and thiobarbiturate associations with VsDapL are supported by molecular dynamics simulations, docking study, overview
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.